Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Shares Outstanding (Weighted Average) (2016 - 2025)

CytomX Therapeutics' Shares Outstanding (Weighted Average) history spans 12 years, with the latest figure at $137.9 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 63.36% year-over-year to $137.9 million; the TTM value through Dec 2025 reached $137.9 million, up 63.36%, while the annual FY2025 figure was $137.9 million, 63.36% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $137.9 million in Q4 2025 per CTMX's latest filing, up from $127.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $137.9 million in Q4 2025 to a low of $14.4 million in Q4 2023.
  • Average Shares Outstanding (Weighted Average) over 5 years is $77.0 million, with a median of $66.4 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): plummeted 78.06% in 2023, then surged 485.45% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $64.1 million in 2021, then grew by 2.48% to $65.7 million in 2022, then tumbled by 78.06% to $14.4 million in 2023, then soared by 485.45% to $84.4 million in 2024, then surged by 63.36% to $137.9 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Shares Outstanding (Weighted Average) are $137.9 million (Q4 2025), $127.4 million (Q3 2025), and $129.1 million (Q2 2025).